Nutriband Inc. (NASDAQ: NTRB) has achieved a significant milestone with the successful completion of commercial manufacturing and scale-up for its AVERSA Fentanyl abuse-deterrent transdermal patch, developed in partnership with Kindeva. This accomplishment has led Robert LeBoyer, Senior Vice President and Equity Research Analyst at Noble Capital Markets, to raise the price target for Nutriband to $15. The AVERSA Fentanyl patch, which utilizes Nutriband's proprietary AVERSA technology, is designed to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The updated report from Noble Capital Markets highlights this milestone as a pivotal moment for Nutriband, enabling the company to move forward with the production of clinical supplies and the submission of an Investigational New Drug (IND) application for a Phase 1 trial. The trial, which follows the 505(b)(2) regulatory pathway, is considered low risk by analysts and aims to demonstrate the patch's reduced appeal to recreational drug users. With the IND application on the horizon, Nutriband is on track to submit a New Drug Application (NDA) between late 2025 and early 2026, with full-year sales projected to commence in FY2027.
LeBoyer's report also revises the FY2027 EPS forecast for Nutriband to $1.57, citing the company's adherence to its projected timeline and the avoidance of an anticipated Q1 2025 equity raise. This positive adjustment reflects confidence in Nutriband's strategic direction and the potential impact of the AVERSA Fentanyl patch on the market. The development of abuse-deterrent formulations is a critical area in the pharmaceutical industry, addressing the growing concern over opioid abuse and misuse. Nutriband's progress with the AVERSA technology not only positions the company as a leader in this space but also underscores the importance of innovation in combating drug abuse.
For more details on the report and Nutriband's advancements, interested parties can access the full analysis through the provided link. This development represents a significant step forward in the fight against opioid abuse, offering a promising solution to a pressing public health challenge.
